ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
An Engineered Supramolecular Pathway for Enhanced Electrochemiluminescence.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Electrochemiluminescence (ECL) underpins ultrasensitive clinical assays, yet current platforms are largely dominated by antibody‒antigen immunoassay formats, which are intrinsically difficult to translate to small-molecule detection. The limited size of small molecules, together with the lack of multiple accessible epitopes, restricts the applicability of conventional sandwich architectures and calls for alternative recognition strategies capable of directly coupling molecular binding to ECL signal generation. Herein, we introduce a supramolecular ECL approach in which a recognition unit (cucurbit[7]uril) is covalently integrated with an ECL-active luminophore (tris(2,2'-bipyridyl)ruthenium(II), [Ru(bpy)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.